Overview
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Description
Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial.
Eligibility
Inclusion Criteria:
- Male or female patients' age from 18 years to 70 years.
- Patients who have a life expectancy of at least 3 months.
- pathologically confirmed non-small cell lung cancer.
- failed in previous standard chemotherapy and targeted therapy.
- Karnofsky performance status 0-1.
- adequate organ functions.
Exclusion Criteria:
- Pregnant and lactating women.
- Patients with T cell lymphoma, syphilis, AIDS or combination
- Patients with highly allergic or have a history of severe allergies
- Patients with severe hepatic or renal dysfunction
- Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
- Patients with severe infection not controlled or High fever
- Patients with organ transplantation or waiting for organ transplantation.
- Patients with brain metastasis
- Patients with severe coagulopathy (e.g. hemophilia)
- Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.